MBRX
Closed
Moleculin Biotech Inc
0.3245
+0.0226 (+7.49%)
Last Update: 01 Jul 2025 23:20:00
Yesterday: 0.3019
Day's Range: 0.29111 - 0.33
Send
sign up or login to leave a comment!
When Written:
0.92
Moleculin Biotech Inc. is a clinical-stage pharmaceutical company focused on the development of innovative cancer therapies. The company's lead product candidate is Annamycin, a liposome-encapsulated anthracycline that is being developed for the treatment of relapsed or refractory acute myeloid leukemia (AML). Moleculin is also developing WP1066, a small molecule inhibitor of STAT3, which is being evaluated as a potential treatment for brain tumors and other cancers.
In addition to its lead candidates, Moleculin is exploring the potential of other compounds in its pipeline, including WP1220, a topical formulation of the anti-cancer agent WP1066, and WP1732, a prodrug of WP1066 that is being developed for the treatment of pancreatic cancer.
Moleculin was founded in 2015 and is headquartered in Houston, Texas. The company is publicly traded on the NASDAQ exchange under the ticker symbol MBRX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
In addition to its lead candidates, Moleculin is exploring the potential of other compounds in its pipeline, including WP1220, a topical formulation of the anti-cancer agent WP1066, and WP1732, a prodrug of WP1066 that is being developed for the treatment of pancreatic cancer.
Moleculin was founded in 2015 and is headquartered in Houston, Texas. The company is publicly traded on the NASDAQ exchange under the ticker symbol MBRX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








